Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12) at ISLB 2026

Nov 7–9, 2026 Madrid, Spain ~700 attendees Website

Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12) brings 3 presentations to ISLB 2026 in Madrid, its home city. Its work centres on following HER2-positive breast cancer during trastuzumab deruxtecan treatment through blood markers such as extracellular vesicles and immune cells. One study measures HER2 on small vesicles in plasma to track response, and another asks how macrophages shape tumour hybrid cell formation in bladder cancer models.

OrganizationISLB 2026 Attendance
imas12.es
Universities & research institutes
Health research institute of the 12 de Octubre University Hospital in Madrid.
Poster
Poster
Poster
Part of Poster sessions
Peripheral Immune Profiling by Multiparametric Flow Cytometry in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Deruxtecan
Clinical use · New analytes
Collaborators: Hospital Universitario 12 de Octubre

Explore the full ISLB 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ISLB 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12)

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the International Society of Liquid Biopsy (ISLB). Submit a correction